Cargando…
Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition
SARS-CoV-2 infection continues to cause increased morbidity and mortality, and due to the slow pace of vaccination COVID-19 will probably remain a global burden to health systems for a long time. Unfortunately, the necessary prevention and treatment strategies of COVID-19 have led to restriction mea...
Autores principales: | Vuorio, Alpo, Strandberg, Timo E., Raal, Frederik, Santos, Raul D., Kovanen, Petri T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349422/ https://www.ncbi.nlm.nih.gov/pubmed/34622243 http://dx.doi.org/10.1016/j.athplu.2021.08.001 |
Ejemplares similares
-
Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation
por: Vuorio, Alpo, et al.
Publicado: (2021) -
Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge
por: Vuorio, Alpo, et al.
Publicado: (2021) -
Opportunities for preventing further endothelial dysfunction in pregnant COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2022) -
Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction
por: Kovanen, Petri T., et al.
Publicado: (2021) -
Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)